VaxForm, LLC

VaxForm, LLC is a privately held American vaccine development company headquartered in the Lehigh Valley region of Pennsylvania, with a mailing address in Bethlehem, Pennsylvania. The company is led by its founder and President, Garry Morefield, Ph.D., a formulation scientist who previously served as head of formulation and stability at Sanofi Pasteur and worked on biodefense vaccine development at the United States Army Medical Research Institute of Infectious Diseases. VaxForm positions itself as a specialist in vaccine formulation, adjuvant development, and process development, with a particular emphasis on aluminum adjuvants and novel delivery approaches. The company's most visible public program is an oral COVID-19 vaccine candidate developed on its QYNDR platform. VaxForm has published a manuscript in the journal Vaccines describing the development of this oral COVID vaccine, signaling an active research and publication effort around needle-free, orally administered vaccine technology. This work places VaxForm in the broader field of next-generation vaccine delivery, where oral and mucosal immunization are pursued to improve access, simplify logistics, and reduce reliance on injections. VaxForm's team includes scientists with experience across bacterial and viral vaccine targets. Deputy Director of Process Development Elodie Burlet, Ph.D., brought more than eight years of vaccine R&D experience to the company, having worked on formulation development for pathogens including Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, rabies, diphtheria/tetanus/pertussis combination vaccines, HIV, Neisseria meningitidis, and SARS-CoV-2, as well as immunotherapies for non-infectious diseases such as Alzheimer's. This breadth reflects VaxForm's contract-research and collaborative capabilities as well as its internal pipeline ambitions. As a small private company, VaxForm does not disclose detailed financial information, ownership structure, or a public listing. Its public presence centers on its website, scientific publications, and contact channels for partnership or inquiry. The company's stated focus on formulation and adjuvant expertise, combined with its oral vaccine platform, defines its identity within the vaccine development ecosystem.

VaxForm, LLC was founded by Garry Morefield, Ph.D., who has served as its President for 13 years as of the company's public biography. Before founding VaxForm, Morefield was head of formulation and stability at Sanofi Pasteur, where he worked on bacterial and viral vaccine targets from preclinical development through clinical phases and marketed products, including seasonal and pandemic influenza, pneumococcal and meningococcal conjugates, meningococcal group B, C. difficile, hepatitis B, inactivated polio, diphtheria, tetanus, pertussis, and combination vaccine products. He also gained biodefense vaccine development experience at the United States Army Medical Research Institute of Infectious Diseases, participating in formulation development for Streptococcal enterotoxin B, anthrax, plague, and botulinum neurotoxin A vaccines. Morefield is recognized for expertise in adjuvant development and production, including TLR and CTL agonists, squalene-based emulsions, and aluminum salts, and has spoken at research conferences and served as an expert witness in patent prosecutions. The company established itself in the Lehigh Valley region of Pennsylvania, with a mailing address at PO Box 21255, Lehigh Valley, PA 18002, and is described as a company in Bethlehem, United States. VaxForm built its capabilities around vaccine formulation, adjuvant development, and process development, serving both internal programs and potentially collaborative or contract research needs. A significant public milestone came with the publication of a manuscript in the journal Vaccines describing the development of an oral COVID-19 vaccine using the company's QYNDR platform. This publication highlighted VaxForm's work in needle-free, orally administered vaccine technology, an area of growing interest for improving vaccine access and logistics. The company's team grew to include scientists such as Elodie Burlet, Ph.D., who joined as Deputy Director of Process Development with over eight years of vaccine R&D experience spanning bacterial and viral pathogens and immunotherapies for non-infectious diseases. As of its public communications, VaxForm remains a private company with a focused scientific mission, active in vaccine formulation and oral delivery research. Its website, copyright dated 2020, serves as its primary public information channel, inviting inquiries via contact@vaxform.com.

• VaxForm founded by Garry Morefield, Ph.D.

• VaxForm publishes manuscript in journal Vaccines on development of oral COVID vaccine using QYNDR platform

Specialist vaccine formulation and adjuvant development company with a focus on oral vaccine delivery technology.

• QYNDR oral vaccine platform

  Platform for oral vaccine development, used for an oral COVID-19 vaccine candidate.

• Oral COVID-19 vaccine candidate

  Oral COVID vaccine developed using the QYNDR platform; manuscript published in Vaccines.

1. 1VaxForm official websitevaxform.com
2. 2Who We Are - VaxFormvaxform.com
3. 3VaxForm, LLC (United States) - Wikidatawikidata.org